In the following article, practice changing updates on gastrointestinal cancers management have been discussed. For metastatic colorectal cancer with RAS wild-type, fluoropyrimidine plus panitumumab combination has been the preferred maintenance option for patients who have stopped oxaliplatin. The cytoreductive surgery alone showed satisfactory survival outcomes in colorectal cancer patients with peritoneal carcinomatosis. Dose escalation of regorafenib showed better clinical outcomes than the standard dosing regimen. Adjuvant FOLFIRINOX is the new treatment option for selected resected pancreatic cancer patients. Neoadjuvant treatment is the new paradigm for borderline and resectable pancreatic cancer patients. Several options for advanced hepatocellular cancers now available and more clinical studies are required for optimal treatment sequencing. Trifluridine/tipiracil showed improved overall survival in esophageal cancers beyond the second line.